Lobular Research

First ever International #Lobular #breast #cancer symposium. Pittsburgh, PA, USA. Sept 2016. twitter.com/mjsikora/statu…

@BreastDense @PWBDerksen @cancercenterumc @BeingDense- Focused on Lobular & TNBC, the RATHER consortium was a large multidisciplinary collaborative project funded by the EU & led by University College Dublin. ratherproject.com/news.php I’d turn over every stone to find out who was involved w/ ILC advocacy w/ this project.

@PWBDerksen @cancercenterumc Do you have any links to patient advocacy groups in Europe #ILC #Lobular we are interested in collaborating and establishing an Irish Lobular Advo.

Today we hosted the 2nd #Lobular #Breastcancer consortium meeting @cancercenterumc. Excellent sessions with inspiring colleagues working toward a better diagnosis, treatment and understanding of #ILC. #LBCA #ELBCC

@EricTopol @CellStemCell @CellPressNews @StanfordMed Off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell cancer immunotherapy is now available in clinical trials. health.ucsd.edu/news/releases/…

Can induced pluripotent stem cells become a new form of #cancer immunotherapy? cell.com/cell-stem-cell… @CellStemCell @CellPressNews @StanfordMed

Great news!

@oesterreichs @LobularBCA @LPseattle @hiplinemedia @Otto_DFCI @PWBDerksen @c_sotiriou @UPMCHillmanCC @mjsikora @BCRFcure @SusanGKomen This is GREAT news! Thank you!

Save the date May 14-16, 2020, for 2nd International ILC Symposium In #Pittsburgh @LobularBCA #lobmob #Lobular #bcsm @LPseattle @hiplinemedia @Otto_DFCI @PWBDerksen @c_sotiriou @UPMCHillmanCC @mjsikora @BCRFcure @SusanGKomen

#Lobular related abstracts at #AACR19 TMB, PD-L1 status & Checkpoint Inhibitors abstractsonline.com/pp8/?sf1004231… [18F]FDG PET/CT imaging abstractsonline.com/pp8/?sf1004231… NCI-MATCH EAY131 arm B: Phase II study of afatinib in patients with HER2 (ERBB2) activating mutations abstractsonline.com/pp8/?sf1004231…

Great news for the #Lobular breast cancer community. New Lobular Breast Cancer Registry Will Shed Light on Rare Disease consultqd.clevelandclinic.org/new-lobular-br… via @CleClinicMD

@CBrisken @ICPInews Were these immunodeficient mice? just wondering if this mouse model would be useful for investigating cancer immunotherapies?

Susan Potter (breast cancer survivor) gave her body to science. Her cadaver became immortal. nationalgeographic.com/magazine/2019/… via @NatGeo

Small historical studies reveal ~50% of Lobular breast cancers over-express ROR1 (not to be confused with ROS1). If validated, could Anti-ROR1 CAR-T immunotherapy be a future option for mILC? CAR T-Cell Therapy Shows Early Potential in TNBC shar.es/aaYRVD via @onclive

#SABCS18 genomic and immune characterization of lobular breast cancer presented by Dr. Desmedt underscores the fact that lobular breast cancer is different from ductal both clinically and in the mutations that occur. Need to think about optimal treatment strategies! #bcsm

#SABCS18 Desmedt on lobular cancer progression and endocrine resistance. Uses 73 matched primary and mets (great). Increased ESR1, IGF1R, HER2 mutations. Increased AKT1. Each of these has potential to alter therapy.

Impassion 130: PD-L1 expression on TILs best predictor of benefit from atezo (immune checkpoint inhibitor). Even expression at 1% level showed benefit. All metastatic TNBC should be tested for PD-L1 on TILs. #SABCS18 Atezo likely to be FDA approved in this setting in near future

Bringing together Clinical and Biomedical Scientists @cancercenterumc for the 1st European #ILC consortium meeting. Inspiring interactive sessions building towards an improved diagnosis and tailored treatment of #lobular #breastcancer! #ILBC #DerksenLab #UMCUtrecht

More pre-clinical evidence that suggests synergy between CDK4/6 inhibitors and Checkpoint Blockade to overcome resistance. Perhaps endocrine-sensitive tumors like #Lobular could benefit. Clinical trials needed.

@EV11PDX Main center has enrolled ~8 patients in 7 months. Other sites are just opening up. Biopsy is required, so those that have been enrolled have measurable disease, but it's not clear how many have been denied due to unmeasurable disease.

@LobularResearch Any updates on accrual? Any difficulty enrolling patients due to not meeting RECIST?

Worlds first ILC / #Lobular clinical trial using #Immunotherapy [Atezolizumab] launching in Netherlands. Summer 2017 clinicaltrials.gov/show/NCT031470…

Wow! Didn’t realize Dr. Leisha Emens was at UPMC. As a thought leader in immunotherapy for breast cancer, this is a big win for Pitt and perhaps a potential windfall for the #Lobular community.

Intra-lesion genetic heterogeneity in LCIS should be considered in studies aiming to develop biomarkers of progression from LCIS to invasive disease.

Tumor-suppressor genes are often inactivated through changes in mRNA processing that enable expression of truncated proteins. This mechanism of inactivation does not require DNA mutations in the affected genes. mskcc.org/blog/scientist…

Today, hospital said it was reducing $108,000 out-of-pocket bill to $782?! @khnews' @chadterhune @npr. Having a journalist's expose settle a bill is not triumph, it's a symptom of a very broken system, as in my book #AnAmericanSickness khn.org/news/a-jolt-to…